CERENOVUS, Inc., part of Johnson & Johnson MedTech1 has announced that the new CEREPAK™ Detachable Coils are commercially available in the U.S. and that the first patient cases have been performed. CEREPAK is the latest innovation to join the CERENOVUS hemorrhagic portfolio and further demonstrates the company’s commitment to treating hemorrhagic stroke.
The CEREPAK Detachable Coils offer three shapes and multiple coil sizes, providing physicians with comprehensive options to embolize brain aneurysms, including coils shaped specifically to achieve concentric aneurysm filling and contribute large volumetric filling.i,ii,iii,2 CEREPAK provides physicians with a state-of-the-art delivery system designed for ease of use and reliable detachment3, next-generation microcatheter stability4, effortless tracking through tortuous anatomy4, and reduction of radiation (fluoroscopy) exposure with fluoro-saver markers.
“I’m privileged to be one of the first users of the new CEREPAK Detachable Coils,” said Osama O. Zaidat, MD*, Director of the Neuroscience and Stroke Center at Mercy Hospital in Toledo, Ohio and study co-principal investigator of the STERLING Registry, “The advancement of greater tools in neurology may improve patient outcomes and my team looks forward to continuing the utilization of CEREPAK coils in our treatment plans.”
This latest addition to the CERNEOVUS portfolio will also be included in the STERLING Registry which is currently collecting real-world data on ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils.
“The CEREPAK Detachable Coils provide important advancements for embolizing brain aneurysms and we’re pleased to expand the STERLING Registry to include this latest CERENOVUS offering,” said Reade De Leacy, MD*, Neurointerventional Radiologist, Associate Professor of Neurosurgery and Radiology, Mount Sinai Health System and study co-principal investigator of the STERLING Registry.
Brain aneurysms are weak spots in blood vessels that have the potential to rupture and cause bleeding within the brain. Such bleeding can lead to complications, including hemorrhagic stroke, permanent nerve damage or death.iv Each year, about 30,000 people in the U.S. suffer from ruptured brain aneurysms.iv The first treatment of choice for intracranial aneurysms is a minimally invasive coiling procedure, where coils are inserted directly into an aneurysm to fill up space and induce clotting to prevent it from rupturing.v
“At CERENOVUS, we push the boundaries of what is possible in stroke care through continuous innovation,” said Mark Dickinson, Worldwide President, CERENOVUS. “Our main goal is to address unmet clinical needs and improve patient outcomes, and we’re proud to announce this latest addition to our hemorrhagic portfolio that furthers our commitment to changing the trajectory of stroke.”
In support of CERENOVUS’ sustainability commitments, CEREPAK is the first product in the company’s U.S. portfolio to utilize electronic instructions for use (e-IFUs)**. E-IFUs are expected to help reduce the company’s environmental footprint, lower CO2 emissions caused during shipment and facilitate a reduction in healthcare systems’ post-consumer recycling and medical waste disposal. Additionally, the CEREPAK mechanical detachment system reduces waste with the elimination of a disposable battery source needed in traditional electromechanical systems.